The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen (I)
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Novartis; OncLive; Pfizer; Xcenda
Research Funding - Acceleron Pharma; Agensys; Bayer; Bristol-Myers Squibb; Novartis
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Alkermes; Amgen; Bristol-Myers Squibb; C-Cam; Genentech; Genoptix; GlaxoSmithKline; Infinity Pharmaceuticals; Lilly; Merck; Nektar; Novartis; Pfizer; X4 Pharma
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Acceleron Pharma (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Mario Sznol
Consulting or Advisory Role - Amgen; Anaeropharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Kyowa Hakko Kirin; Lion Biotechnologies; Merus; Nektar; Symphony Evolution
Other Relationship - Haymarket Media
 
Saby George
No Relationships to Disclose
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Dendreon; ImmuneXcite; Janssen; Lilly; Merck; NexImmune; Pierre Fabre; Roche/Genentech
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Janssen
Patents, Royalties, Other Intellectual Property - AstraZeneca; Bristol-Myers Squibb; Janssen; MedImmune
 
Brian I. Rini
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Timothy Kuzel
Honoraria - Amgen; Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Bionomics; Celgene; Eisai; Genentech/Roche; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Janssen Oncology
Research Funding - Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); Eisai (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck/Schering Plough (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Celgene; elorac; Genentech; Janssen Oncology
 
Jeffrey Alan Sosman
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; Merck
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Novartis (Inst)
 
David C. Smith
Research Funding - Agensys (Inst); Aragon Pharmaceuticals (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Seagen (Inst); Tekmira (Inst); Teva (Inst)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer
 
John D. Powderly
Employment - BioCytics
Leadership - BioCytics
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amplimmune; AstraZeneca; Bristol-Myers Squibb; Curis; Genentech; Merck
Research Funding - Amplimmune; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genetic Technologies; ImClone Systems; Incyte; Macrogenics
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Aduro Biotech (I); Compugen (I); Five Prime Therapeutics; Jounce Therapeutics (I); NexImmune (I); Potenza Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Five Prime Therapeutics; GlaxoSmithKline; Inanovate; Jounce Therapeutics; MedImmune (I); Merck (I); Pfizer (I); Potenza Therapeutics (I); Sanofi (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Potenza Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Aduro Biotech (I); Bristol-Myers Squibb (I); Potenza Therapeutics (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Five Prime Therapeutics
 
Huanyu Zhao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ian M. Waxman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Hans J. Hammers
Consulting or Advisory Role - Bristol-Myers Squibb; exelixis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Newlink Genetics (Inst); Pfizer (Inst); SFJ Pharmaceuticals Group (Inst); TRACON Pharma (Inst)